eFFECTOR: Positive Interim Data from Dose Escalation, Phase 2 Expansion in ER+ Metastatic Breast Cancer

 Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients

Zotatifin generally well tolerated as dose escalation continues; Currently enrolling at 0.28 mg/kg in the ZF doublet evaluating zotatifin combined with fulvestrant and at 0.1 mg/kg in the ZFA triplet

https://www.globenewswire.com/news-release/2023/12/08/2793183/0/en/eFFECTOR-Therapeutics-Announces-New-Positive-Interim-Data-from-Dose-Escalation-and-Phase-2-Expansion-Cohorts-of-Zotatifin-in-ER-Metastatic-Breast-Cancer-Patients.html